These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1506 related articles for article (PubMed ID: 11407274)

  • 1. [A case of acute psychotic episode after a single dose of ecstasy].
    Vaiva G; Bailly D; Boss V; Thomas P; Lestavel P; Goudemand M
    Encephale; 2001; 27(2):198-202. PubMed ID: 11407274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An "accidental" acute psychosis with ecstasy use.
    Vaiva G; Boss V; Bailly D; Thomas P; Lestavel P; Goudemand M
    J Psychoactive Drugs; 2001; 33(1):95-8. PubMed ID: 11333007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Acute psychosis with aggressive behavior as a consequence of MDMA (Ecstasy) consumption].
    Milas M
    Lijec Vjesn; 2000; 122(1-2):27-30. PubMed ID: 10916354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Alpha-interferon and mental disorders].
    Debien C; De Chouly De Lenclave MB; Foutrein P; Bailly D
    Encephale; 2001; 27(4):308-17. PubMed ID: 11686052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Persisting and late onset psychotic disorder due to consumption of ecstasy (MDMA)].
    Boné Pina I; Ramos Gorostiza P; Villalba Yllán P; Valle Fernández J
    Actas Esp Psiquiatr; 2000; 28(1):61-5. PubMed ID: 10758429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.
    Thomasius R; Zapletalova P; Petersen K; Buchert R; Andresen B; Wartberg L; Nebeling B; Schmoldt A
    J Psychopharmacol; 2006 Mar; 20(2):211-25. PubMed ID: 16510479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Frontal dementia or dementia praecox? A case report of a psychotic disorder with a severe decline].
    Vanderzeypen F; Bier JC; Genevrois C; Mendlewicz J; Lotstra F
    Encephale; 2003; 29(2):172-80. PubMed ID: 14567169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of the acute subjective effects of MDMA/ecstasy.
    Baylen CA; Rosenberg H
    Addiction; 2006 Jul; 101(7):933-47. PubMed ID: 16771886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ecstasy--the status in French-speaking Switzerland. Composition of seized drugs, analysis of biological specimens and short review of its pharmacological action and toxicity].
    Giroud C; Augsburger M; Sadeghipour F; Varesio E; Veuthey JL; Rivier L
    Praxis (Bern 1994); 1997 Mar; 86(13):510-23. PubMed ID: 9157497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lasting neuropsychiatric sequelae of (+-)methylenedioxymethamphetamine ('ecstasy') in recreational users.
    McCann UD; Ricaurte GA
    J Clin Psychopharmacol; 1991 Oct; 11(5):302-5. PubMed ID: 1684975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Psychiatric disorders and consumption of ecstasy drug (MDMA): review of published case reports].
    Bango J; Fadón P; Mata F; Rubio G; Santo-Domingo J
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1998; 26(4):260-3. PubMed ID: 9807860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA ("Ecstasy") and MDA ("Love").
    McNamara R; Kerans A; O'Neill B; Harkin A
    Neuropharmacology; 2006 Jan; 50(1):69-80. PubMed ID: 16188283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [MDMA ("Ecstasy") use--an overview of psychiatric and medical sequelae].
    Thomasius R; Schmolke M; Kraus D
    Fortschr Neurol Psychiatr; 1997 Feb; 65(2):49-61. PubMed ID: 9157047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mental disorders in current and former heavy ecstasy (MDMA) users.
    Thomasius R; Petersen KU; Zapletalova P; Wartberg L; Zeichner D; Schmoldt A
    Addiction; 2005 Sep; 100(9):1310-9. PubMed ID: 16128720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The origin of informed consent].
    Mallardi V
    Acta Otorhinolaryngol Ital; 2005 Oct; 25(5):312-27. PubMed ID: 16602332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma concentrations of 5-HT, 5-HIAA, norepinephrine, epinephrine and dopamine in ecstasy users.
    Stuerenburg HJ; Petersen K; Bäumer T; Rosenkranz M; Buhmann C; Thomasius R
    Neuro Endocrinol Lett; 2002 Jun; 23(3):259-61. PubMed ID: 12080289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mood and cognitive effects of +/-3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'): week-end 'high' followed by mid-week low.
    Curran HV; Travill RA
    Addiction; 1997 Jul; 92(7):821-31. PubMed ID: 9293041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Problematic versus non-problematic ecstasy/MDMA use: the influence of drug usage patterns and pre-existing psychiatric factors.
    Soar K; Turner JJ; Parrott AC
    J Psychopharmacol; 2006 May; 20(3):417-24. PubMed ID: 16574716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The sub-acute effects of recreational ecstasy (MDMA) use: a controlled study in humans.
    Huxster JK; Pirona A; Morgan MJ
    J Psychopharmacol; 2006 Mar; 20(2):281-90. PubMed ID: 16510486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [3,4-methylenedioxymethamphetamine ('ecstasy'): its long-term emotional and cognitive effects, and serotonin depletion].
    Molero-Chamizo A
    Rev Neurol; 2005 Jul 16-31; 41(2):108-14. PubMed ID: 16028190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 76.